Therapeutic time window for angiotensin-(1-7) in acute lung injury

British Journal of Pharmacology

Volumn 173, Issue 10, 2016, Pages 1618-1628

  Supé, Stefanie ^a   Kohse, Franziska ^a,b   Gembardt, Florian ^c,d   Kuebler, Wolfgang M ^a,e,f,g   Walther, Thomas ^b,h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Excellencecluster Cardio Pulmonary System Department of Internal Medicine   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^h UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE; MYELOPEROXIDASE; OLEIC ACID; TUMOR NECROSIS FACTOR ALPHA; ANGIOTENSIN I; ANGIOTENSIN I (1-7); PEPTIDE FRAGMENT;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA FLOW; ARTERIAL PRESSURE; ARTICLE; CENTRAL VENOUS PRESSURE; CONTINUOUS INFUSION; CONTROLLED STUDY; HEART LEFT ATRIUM PRESSURE; LUNG ARTERY PRESSURE; LUNG EDEMA; LUNG VASCULAR RESISTANCE; LUNG WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTEMIC VASCULAR RESISTANCE; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; TIME FACTOR;

ACUTE LUNG INJURY; ANGIOTENSIN I; ANIMALS; HEMODYNAMICS; INFUSIONS, INTRAVENOUS; MALE; OLEIC ACID; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84961827848     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13462     Document Type: Article

References (43)

1. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024-6109.
2. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015b). The Concise Guide to PHARMACOLOGY 2015/16: G Protein-Coupled Receptors. Br J Pharmacol 172: 5744-5869.
3. Balingit PP, Armstrong DG, Reyzelman AM, Bolton L, Verco SJ, Rodgers KE, et al., (2012). NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Repair Regen 20: 482-490.
4. Boyle AJ, Mac Sweeney R, McAuley DF, (2013). Pharmacological treatments in ARDS; a state-of-the-art update. BMC Med 11: 166.
5. Bueltmann M, Kong X, Mertens M, Yin N, Yin J, Liu Z, et al., (2009). Inhaled milrinone attenuates experimental acute lung injury. Intensive Care Med 35: 171-178.
6. Chappel MC, Iyer SN, Diz DI, Ferrario CM, (1998). Antihypertensive effects of angiotensin-(1-7). Braz J Med Biol Res 31: 1205-1212.
7. Chen L, Xiao J, Li Y, Ma H, (2011). Ang-(1-7) might prevent the development of monocrotaline induced pulmonary arterial hypertension in rats. Eur Rev Med Pharmacol Sci 15: 1-7.
8. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPA, Giembycz MA, et al., (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 2671-2674.
9. Derian CK, Santulli RJ, Rao PE, Solomon HF, Barrett JA, (1995). Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J Immunol 154: 308-317.
10. Faber F, Gembardt F, Sun X, Mizutani S, Siems WE, Walther T, (2006). Lack of angiotensin II conversion to angiotensin III increases water but not alcohol consumption in aminopeptidase A-deficient mice. Regul Pept 136: 130-137.
11. Gembardt F, Sterner-Kock A, Imboden H, Spalteholz M, Reibitz F, Schultheiss HP, et al., (2005). Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 26: 1270-1277.
12. Herridge MS, Tansey CM, Matté A, Tomlinson G, Diaz-Granados N, Cooper A, et al., (2011). Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 364: 1293-1304.
13. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al., (2005). Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436: 112-116.
14. Johnson ER, Matthay MM, (2010). Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv 23: 243-252.
15. Kilkenny C, Browne W, Ic C, Emerson M, Altman DG, NC3Rs Reporting Guidelines Working Group (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
16. Klein N, Gembardt F, Supé S, Kaestle SM, Nickles H, Erfinanda L, et al., (2013). Angiotensin-(1-7) protects from experimental acute lung injury. Crit Care Med 41: e334-e343.
17. Kuebler WM, Abels C, Schuerer L, Goetz AE, (1996). Measurement of neutrophil content in brain and lung tissue by a modified myeloperoxidase assay. Int J Microcirc 16: 89-97.
18. Li Y, Cao Y, Zeng Z, Liang M, Xue Y, Xi C, et al., (2015). Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathways. Sci Rep 5: 8209.
19. Liu GC, Oudit GY, Fang F, Zhou J, Scholey JW, (2012). Angiotensin-(1-7)-induced activation of ERK1/2 is cAMP/protein kinase A-dependent in glomerular mesangial cells. Am J Physiol Renal Physiol 302: F784-F790.
20. Matthay MA, Ware LB, Zimmerman GA, (2012). The acute respiratory distress syndrome. J Clin Invest 122: 2731-2740.
21. Matute-Bello G, Downey G, Moore BB, Groshong SD, Matthay MA, Slutsky AS, et al., (2011). An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol 44: 725-738.
22. McAuley DF, Laffey JG, O'Kane CM, Perkins GD, Mullan B, Trinder TJ, et al., (2014). Simvastatin in the acute respiratory distress syndrome. N Engl J Med 37: 1695-1703.
23. McGrath JC, Lilley E, (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189-3193.
24. Meng Y, Yu CH, Li W, Li T, Luo W, Huang S, et al., (2014). Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas axis protects against lung fibrosis by inhibiting the MAPK/NF-κB pathway. Am J Respir Cell Mol Biol 50: 723-736.
25. Meng Y, Li T, Zhou GS, Chen Y, Yu CH, Pang MX, et al., (2015). The angiotensin-converting enzyme 2/Angiotensin (1-7)/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA/Rho kinase pathway. Antioxid Redox Signal 22: 241-258.
26. Moore TM, Chetham PM, Kelly JJ, Stevens T, (1998). Signal transduction and regulation of lung endothelial cell permeability. Interaction between calcium and cAMP. Am J Physiol 275: L203-L222.
27. Mordwinkin NM, Russel JR, Burke AS, Dizerega GS, Louie SG, Rodgers KE, (2012). Toxicological and toxicokinetic analysis of angiotensin (1-7) in two species. J Pharm Sci 101: 373-380.
28. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SPH, Buneman OP, et al., NC-IUPHAR(2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
29. Peiró C, Vallejo S, Gembardt F, Azcutia V, Heringer-Walther S, Rodríguez-Mañas L, et al., (2007). Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. J Hypertens 25: 2421-2425.
30. Peiró C, Vallejo S, Gembardt F, Palacios E, Novella S, Azcutia V, et al., (2013). Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas. J Physiol 591 (Pt 9): 2275-2285.
31. Pham H, Schwartz BM, Delmore JE, Reed E, Cruickshank S, Drummond L, et al., (2013). Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy. Cancer Chemother Pharmacol 71: 965-972.
32. Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, et al., (2009). Has mortality from acute respiratory distress syndrome decreased over time?: a systematic review. Am J Crit Care Med 179: 220-227.
33. Ranieri VM, Rubenfeld VM, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al., (2012). Acute respiratory distress syndrome: the Berlin definition. JAMA 307: 2526-2533.
34. Reutershan J, Basit A, Galkina EV, Ley K, (2005). Sequential recruitment of neutrophils into lung and bronchoalveolar lavage fluid in LPS-induced acute lung injury. Am J Physiol Lung Cell Mol Phsiol 289: L807-L815.
35. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al., (2015). Incidence and outcomes of acute lung injury. N Engl J Med 353: 1685-1693.
36. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al., (2003). Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258-8263.
37. Santos RA, (2014). Angiotensin-(1-7). Hypertension 63: 1138-1147.
38. Schuster DP, (1994). ARDS: clinical lessons from the oleic acid model of acute lung injury. Am J Respir Crit Care Med 149: 245-260.
39. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Díez-Freire C, Dooies A, et al., (2010). The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 182: 1065-1072.
40. Slutsky AS, Ranieri VM, (2013). Ventilator-induced lung injury. N Engl J Med 369: 2126-2136.
41. Wösten-van Asperen RM, Lutter R, Specht PA, Moll GN, van Woensel JB, van der Loos CM, et al., (2011). Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J Pathol 225: 618-627.
42. Zambelli V, Bellani G, Borsa R, Pozzi F, Grassi A, Scanziani M, et al., (2015). Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental acute respiratory distress syndrome. Intensive Care Med Exp 3: 44.
43. Zhou P, Cheng CP, Li T, Ferrario CM, Cheng HJ, (2015). Modulation of cardiac L-type Ca2+ current by angiotensin-(1-7): normal versus heart failure. Ther Adv Cardiovasc Dis 9: 342-53.